Let the partnering begin! Biotech investment takes centre stage at Australia Biotech Invest 2014
Two days of intensive discussion at Australia Biotech Invest 2014 will commence tomorrow to highlight the innovation and positive momentum happening in the Australian life sciences sector.
The two-day conference at the Crown Conference Centre provides over 30 expert speakers and panellists, plus 30 presenting biotech companies, to more than 250 delegates from Australia’s life science investor community.
Australia’s biotechnology industry is growing steadily and its trajectory despite the global financial crisis (GFC) has made it one of the standout performers in the national economy. A recent Scientific American survey of the international biotechnology industry ranked Australia fourth among industrialised nations for biotechnology innovation.
Dr Anna Lavelle, the CEO of AusBiotech, said: “For a long time, the GFC chilled speculative investment and people looked for safe options. But they now recognise the need to diversify their portfolios, and see investment in the life sciences as a key component because the sector’s fundamentals have been so consistently robust.
“Our biotechnology industry’s export performance has been flying low, fast and quietly under the radar. Our biopharmaceutical exports have grown to more than $4 billion annually, substantially greater than either the wine and automotive industries, which have a high public profile.
“The industry has become more mature and sophisticated in the past half-decade, with a much better understanding of capital markets, and of what today’s investors want,” she said.
To learn more about Biotech Invest events, visit http://www.ausbiotechinvest.com.
Special edition of Ahead of the Curve profiles investment case for biotech
To coincide with Australia Biotech Invest, the 2014 edition of Ahead of the Curve, ‘Future Proof: The investment case for biotech’, highlights the compelling investment thesis of the biotechnology and life sciences sector. In this special edition, AusBiotech profiles 15 companies that exemplify the diversity and innovation of Australia’s biomedical sciences industry
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...
